↓ Skip to main content

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma

Overview of attention for article published in Journal of Clinical Oncology, July 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
Published in
Journal of Clinical Oncology, July 2009
DOI 10.1200/jco.2008.21.3660
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Geographical breakdown
Country Count As %
Spain 1 1%
Unknown 79 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 13 16%
Student > Bachelor 9 11%
Student > Ph. D. Student 8 10%
Professor > Associate Professor 7 9%
Other 6 8%
Other 19 24%
Unknown 18 23%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 34 43%
Engineering 3 4%
Unspecified 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Nursing and Health Professions 2 3%
Other 7 9%
Unknown 30 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2026.
All research outputs
#4,364,477
of 32,994,287 outputs
Outputs from Journal of Clinical Oncology
#10,764
of 30,530 outputs
Outputs of similar age
#17,963
of 163,133 outputs
Outputs of similar age from Journal of Clinical Oncology
#65
of 191 outputs
Altmetric has tracked 32,994,287 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 30,530 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.5. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,133 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 191 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.